News
The most profitable trades in history often begin in moments of panic. And few moments felt more hopeless than the fall of 2008… As more and more borrowers began defaulting on their mortgages, the ...
The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...
DEAR DR. ROACH: I am a 52-year-old woman who was diagnosed with familial hypercholesterolemia in October 2024. I went through a cardiac workup for pain in my left arm and found this out.
Feeding rats edible microbeads designed to absorb fat helps them lose weight. One day the beads could be used in human foods and drinks to prevent or treat obesity in people.
14h
MedPage Today on MSNGood News on GLP-1s and Cancer Risk, With One Exception
With follow-up ranging from 1 to 11 years, use of GLP-1 agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide ...
The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results